Furthermore, simvastatin-reversed doxorubicin mediates resistance in unmated chronic lymphocytic leukemia (CLL) cells via upregulating Ras/ERK1-2, RhoA/RhoA kinase, Akt, HIF-1, and P-gp activities [282]. Here, RHOA is linked to B-cell chronic lymphocytic leukemia.